Keros Therapeutics Presents Additional Clinical Data from Its Rinvatercept Program at the 2026 MDA Clinical & Scientific Conference
MWN-AI** Summary
Keros Therapeutics, Inc. (Nasdaq: KROS) has announced promising updates regarding its lead product candidate, rinvatercept (KER-065), derived from its Phase 1 clinical trial during the 2026 Muscular Dystrophy Association Clinical & Scientific Conference. Keros is focused on developing treatments for conditions related to dysfunctional signaling of the transforming growth factor-beta (TGF-ß) family of proteins, and rinvatercept is designed to mitigate muscle and bone degeneration.
In the Phase 1 trial, conducted on healthy male volunteers, rinvatercept exhibited safety and tolerability across all tested dose levels without any serious adverse events. Preliminary topline results indicated significant changes in patients’ body composition, including increased muscle mass, reduced fat mass, and improved bone mineral density—all effects suggestive of activin and myostatin inhibition. Comprehensive proteomic analysis confirmed these outcomes, linking rinvatercept's mechanism to anti-inflammatory and anti-fibrotic actions.
With the encouraging results, Keros is now aiming to advance rinvatercept into two exciting Phase 2 clinical trials, targeting Duchenne muscular dystrophy (DMD) and amyotrophic lateral sclerosis (ALS). Data presented also included preclinical studies showing beneficial impacts of rinvatercept in animal models of both diseases, further bolstering its therapeutic potential.
Rinvatercept, a modified ligand trap, is engineered to enhance muscle and bone regeneration by inhibiting myostatin and activin A – proteins that hinder muscle and bone mass. Keros is strategically positioned to lead advancements in treating neuromuscular diseases, harnessing their expertise in TGF-ß proteins to develop transformative therapies. However, investors should remain cautious of potential risks, including competition and funding challenges as noted in Keros' forward-looking statements.
MWN-AI** Analysis
Keros Therapeutics, Inc. (Nasdaq: KROS) has recently showcased promising data from its Phase 1 clinical trial of rinvatercept (KER-065) at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference. This data reinforces the therapeutic promise of rinvatercept in treating neuromuscular diseases, particularly Duchenne muscular dystrophy (DMD) and amyotrophic lateral sclerosis (ALS). The company's focus on developing therapies that inhibit the transforming growth factor-beta (TGF-ß) family suggests a broad potential market.
Investors should consider several key points. First, the trial results indicated that rinvatercept was well-tolerated across all dose levels, with no significant adverse effects noted. The documented increases in muscle mass, decreases in fat mass, and increases in bone mineral density are particularly encouraging. These physiological improvements signal a mechanism of action that may be beneficial in treating muscle-degenerative diseases—a compelling narrative for future phases of the drug's development.
Keros plans to progress rinvatercept into two Phase 2 trials, which will be crucial for determining its efficacy in a patient population. The market potential for effective treatments in DMD and ALS is significant, reflected in the growing demand for innovative therapeutics in rare diseases.
That said, volatility is intrinsic to clinical-stage companies like Keros. While the current data is encouraging, the company’s reliance on upcoming clinical trials means investors should be aware of potential risks, including delays or setbacks in clinical outcomes. Keros will also need to secure funding for continued development, adding another layer of risk.
In summary, Keros Therapeutics' stock may present a speculative but potentially rewarding opportunity within biotech investing, particularly as it ventures into crucial clinical trials. Prospective investors should stay informed about trial progress and market developments, balancing optimism with an awareness of inherent risks in the biotech sector.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
LEXINGTON, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that it presented additional data from its Phase 1 clinical trial of rinvatercept (KER-065) in healthy volunteers at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference.
“We are pleased to present additional data that further underscore the wide-ranging therapeutic potential of rinvatercept,” said Jasbir S. Seehra, President and Chief Executive Officer of Keros. “These data continue to reinforce the potential of rinvatercept to treat neuromuscular diseases, and our focus remains on advancing the rinvatercept program into two Phase 2 clinical trials, one in Duchenne muscular dystrophy (“DMD”) and one in amyotrophic lateral sclerosis (“ALS”).”
Clinical Presentation
Proteome Analysis in a Phase 1 Trial of KER-065, a Modified Activin Receptor Ligand Trap, Confirmed Target Engagement and Guides Clinical Development in Neuromuscular Diseases
This Phase 1 clinical trial was a randomized, double-blind, placebo-controlled, two-part dose escalation (single and multiple ascending dose) trial in healthy adult male volunteers. The primary objectives of this trial were to assess safety, tolerability and pharmacokinetics of rinvatercept. Exploratory proteomic analysis was performed on serum samples.? Differential expression analysis was used to compare protein levels in serum samples from volunteers who received rinvatercept or placebo over 71 days.? Initial topline data from this trial was reported in March 2025.
As previously reported, treatment with rinvatercept was generally well-tolerated at all dose levels evaluated. No dose-limiting toxicities or serious adverse events were reported.
Administration of rinvatercept led to changes in body composition consistent with activin and myostatin inhibition. An increase in muscle mass, decrease in fat mass and an increase in bone mineral density were observed.
Proteomic data further demonstrated the mechanism of action of rinvatercept, including its observed effects on mitigating fibrosis and inflammation by inhibiting activins, consistent with the anti-fibrotic and anti-inflammatory effects observed preclinically. Changes in serum markers of energy metabolism indicated a shift in macronutrient requirements for muscle growth, which aligned with the observed increases in muscle mass. These data provide multiple lines of evidence that rinvatercept may potentially achieve sufficient activin inhibition across tissues of interest, at drug exposures that we anticipate targeting in DMD and ALS.
Preclinical Presentations
Additionally, the Company presented the following preclinical presentations from its rinvatercept program that continue to support the further development of rinvatercept in DMD and ALS:
- RKER-065 Improved Muscle and Bone Mass and Strength in the D2.mdx Mouse Model of Duchenne Muscular Dystrophy
- RKER-065 Exhibited Beneficial Effects in an Amyotrophic Lateral Sclerosis Mouse Model
About Rinvatercept
Rinvatercept is a novel ligand trap comprised of a modified ligand-binding domain derived from activin receptor type IIA and activin receptor type IIB that is fused to the portion of the human antibody known as the Fc domain. Rinvatercept is designed to act as a ligand trap and inhibit the biological effects of myostatin and activin A, which are negative regulators of muscle and bone mass and strength, to improve skeletal muscle regeneration, increase muscle size and strength, inhibit and reduce fibrosis, inhibit inflammation, reduce fat accumulation and improve bone health through bone anabolic mechanisms. We are developing rinvatercept for the treatment of DMD and for the treatment of ALS.
About Keros Therapeutics, Inc.
Keros is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the TGF-ß family of proteins. Keros is a leader in understanding the role of the TGF-ß family of proteins, which are master regulators of the growth, repair and maintenance of a number of tissues, including skeletal muscle, bone, adipose, heart tissue and blood. By leveraging this understanding, Keros has discovered and is developing protein therapeutics that have the potential to provide meaningful and potentially disease-modifying benefit to patients. Keros’ lead product candidate, rinvatercept, is being developed for the treatment of DMD and for the treatment of ALS. Keros’ most advanced product candidate, elritercept, is being developed for the treatment of cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndrome and in patients with myelofibrosis.
Cautionary Note Regarding Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as “potential” or similar expressions are intended to identify forward-looking statements. Examples of these forward-looking statements include statements concerning: Keros’ expectations regarding its strategy and timing of its two Phase 2 clinical trials for rinvatercept; and the potential of rinvatercept to treat neuromuscular diseases, including DMD and ALS. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, among others: Keros’ limited operating history and historical losses; Keros’ ability to raise additional funding to complete the development and any commercialization of its product candidates; Keros’ dependence on the success of its product candidates, rinvatercept and elritercept; that Keros may be delayed in initiating, enrolling or completing any clinical trials; competition from third parties that are developing products for similar uses; Keros’ ability to obtain, maintain and protect its intellectual property; and Keros’ dependence on third parties in connection with manufacturing, clinical trials and preclinical studies.
These and other risks are described more fully in Keros’ filings with the Securities and Exchange Commission (“SEC”), including the “Risk Factors” section of the Company’s Annual Report on Form 10-K, filed with the SEC on March 4, 2026, and its other documents subsequently filed with or furnished to the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except to the extent required by law, Keros undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
Contacts
Investor Contact:
Justin Frantz
jfrantz@kerostx.com
617-221-6042
Media Contact:
Mahmoud Siddig / Adam Pollack / Viveca Tress
Joele Frank, Wilkinson Brimmer Katcher
(212) 355-4449
FAQ**
What are the key milestones the company plans to achieve in its Phase 2 trials for rinvatercept (Keros Therapeutics Inc. KROS) in the treatment of DMD and ALS, and how do they plan to address potential delays in these trials?
Given the promising data from the Phase 1 trial of rinvatercept, how does Keros Therapeutics Inc. KROS plan to secure funding for continued development, especially if additional trials are required?
Can Keros Therapeutics Inc. KROS provide insights into the competitive landscape for DMD and ALS treatments, and how rinvatercept differentiates itself from other therapies in development?
What strategies does Keros Therapeutics Inc. KROS have in place to protect its intellectual property related to rinvatercept, and how critical is this for the company’s long-term success?
**MWN-AI FAQ is based on asking OpenAI questions about Keros Therapeutics Inc. (NASDAQ: KROS).
NASDAQ: KROS
KROS Trading
3.6% G/L:
$11.21 Last:
331,187 Volume:
$10.95 Open:
